DEA Starts 6-Hour Inspections at Medical Marijuana Dispensaries After Schedule III Shift
Updated
Updated · Marijuana Moment · Jun 18
DEA Starts 6-Hour Inspections at Medical Marijuana Dispensaries After Schedule III Shift
3 articles · Updated · Marijuana Moment · Jun 18
Summary
Two Mississippi medical marijuana dispensaries were visited by DEA teams of 5-6 officials last week after registering for new federal protections tied to marijuana’s move from Schedule I to Schedule III.
At High Street Dispensary in Jackson, agents spent about six hours touring the facility, asking detailed questions on hours, inventory and operations; the business owner described the tone as cordial and collaborative.
DEA also requested extensive records during the visits, including ownership changes, vendor lists, full inventory, employee files, security plans, METRC purchase history and a requirement to post 24-hour surveillance signage.
The inspections follow DEA’s April launch of a dispensary registration form after Acting Attorney General Blanche ordered state-licensed medical marijuana products moved to Schedule III, with broader rescheduling hearings due later this month.
That shift could let registered cannabis businesses claim federal tax deductions now barred under IRS code 280E, while DEA plans to expand registration forms to manufacturers, distributors and laboratories.
Cannabis firms can now save millions on taxes. What is the hidden cost of accepting federal DEA oversight?
With medical cannabis now federally recognized, is a full pharmaceutical takeover of the marijuana industry inevitable?
Medical marijuana users may soon legally buy guns, but could a legal loophole still put them at risk?
Schedule III Cannabis: How 2026 Federal Reclassification Transforms Medical Marijuana Policy, Compliance, and Industry Prospects
Overview
The recent reclassification of medical marijuana from Schedule I to Schedule III marks a major shift in federal cannabis policy, recognizing its accepted medical use and lower potential for dependence. This change allows state-licensed medical marijuana businesses to access federal benefits, such as tax deductions, and enables researchers to work with state-licensed cannabis without penalties. The DEA has started a registration process for these businesses, but challenges remain, including legal pushback, ongoing regulatory uncertainties, and a clear divide between medical and recreational cannabis. The upcoming DEA hearing will further shape the future of federal cannabis policy.